Atrial fibrillation in 2010: advances in treatment and management.

Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf (2013) 1.23

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51

Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J (2010) 2.46

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J (2010) 1.11